News

Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain
Jyong Biotech targets urinary disorders with a novel botanical pipeline, but clinical and liquidity risks temper near-term ...
Lawmakers press FDA to target knockoff weight-loss drug
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...
JD Supra22h
Before it hits the shelf: FDA reprocesses the new dietary ingredient notification process
On June 11, 2025, the US Food and Drug Administration (FDA) released educational materials to broaden dietary supplement manufacturers’ ...
Inventor claims bleach injections will destroy cancer tumors
Xuewu Liu, a Chinese inventor who has no medical training or credentials of any kind, is charging cancer patients $20,000 for ...
Houston-based Empower Pharmacy’s drugs raised red flags for FDA and other states, but not Texas
Empower Pharmacy, a Houston-based compounding pharmacy, has been sanctioned by the FDA and other states in the past decade.
Physician's Weekly1d
FDA Upgrades Recall on 160,000+ Bottles of Thyroid Medication
The U.S. Food and Drug Administration (FDA) has upgraded a recall of a commonly prescribed thyroid medication due to what it ...
JD Supra1d
Beyond Guinea Pigs: Patent Risks and Opportunities in AI-Enabled Drug Development
On April 10, 2025, the U.S. Food and Drug Administration (FDA) announced a landmark initiative to phase out animal testing in ...
The American Journal of Managed Care1d
RP1 Plus Nivolumab Receives CRL for Advanced Melanoma
The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...
Sarepta drops as report suggests FDA needs new trials for Elevidys
Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...